The aim of our study was to investigate a predictive and whole-tissue based easy-to-implement biomarker for RCC, and excitingly, CTLA4 promoter methylation seems to have cancer-independent predictive potential for ICB response in melanoma and RCC.16 17. The gene discussed is CTLA4; the disease is cancer.